Shots:

• The P-I trial involves assessing of Stelara (US or EU) vs NeuLara in 210 patients in ratio (1:1:1) and resulted in no serious adverse events with anticipated results in Q3’20
• NeuLara is one of the biosimilars developed in collaboration with NeuClone and Serum Institute of India Pvt Ltd (Serum Institute). In 2009- Stelara was launched in the US and its Wholesale Acquisition Cost (WAC) increased by 136%
• NeuClone has a pipeline of biosimilars referencing Herceptin- Stelara- Synagis- Prolia/XGEVA- Perjeta and Humira developed using its NeuMAX platform

Click here to read full press release/ article | Ref: Neuclone | Image: Signbox